

20 May 2015

www.intgold.com.au

Company Announcements Office
Australian Securities Exchange
Level 6, 20 Bridge Street
SYDNEY NSW 2000

Via E Lodgement

WINTER GARDEN BIOSCIENCES FURTHER ENHANCES EXPERT TEAM TO DRIVE PRODUCT DEVELOPMENT AND BUSINESS EXECUTION

International Goldfields Ltd (ASX: IGS) (“**IGS**” or the “**Company**”) is pleased to provide an update from Winter Garden Biosciences (“**Winter Garden**” or “**WG**”) on recent key appointments to its executive team that will be instrumental in driving the business going forward. WG is a Uruguayan biosciences and pharmaceutical company in which IGS has agreed to acquire an 85% interest (refer ASX announcement dated 1 May 2015).

Research to packaged product for export all in-house

Winter Garden sets itself apart from other industry participants by controlling every phase of the its business from research and testing for product creation all the way through to a fully finished and packaged product for the end user. This one-stop-shop infrastructure allows Winter Garden to innovate and deliver its medical solutions at a considerably lower cost and in a much shorter timeframe than its competition.

WG has been offered an exciting opportunity to assist the cannabis and hemp research industry in proceeding with multiple clinical trials for formulation and drug delivery with select lab service partners which are internationally recognised for their history in drug development.

An integral step on the path to bioceutical and pharmaceutical patents is stabilisation and genetic registration of valuable cultivars. Such standardisation can only be achieved through rigorous control of growth environment and genetic isolation, a service WG will offer to its partners and the research community as a whole to help push current legislative barriers into the next phase of medical marijuana research. This is a value that no private company or public institution has been able to offer and will place WG as an industry leader and innovator for years to come.

Julian Strauss, the founder of Winter Garden, stated: “*We are fortunate to be so well placed with our state of the art laboratory and access to a to high quality personnel courtesy of our relationships with top academic institutions in the country - our ability to scale human resources economically will be critical to our growth as we build out the business.*”

BOARD

Michael Edwards
Chairman

David Tasker
Director

Travis Schwertfeger
Director

COMPANY SECRETARY

Jane Flegg

REGISTERED OFFICE AND PRINCIPLE PLACE OF BUSINESS

Ground Floor, 1 Havelock Street
WEST PERTH WA 6005

PO Box 684
WEST PERTH WA 6872

COMMUNICATION DETAILS

Telephone: +61 8 9488 5220
Facsimile: +61 8 9324 2400

Web Address:
www.intgold.com.au
Email Address:
info@intgold.com.au

AUSTRALIAN BUSINESS NUMBER

69 099 544 680

SHARE REGISTRY

Advanced Share
Registry Services Pty Ltd
150 Stirling Hwy
Nedlands WA 6009

MEDIA CONTACT

Tony Dawe
PPR

T: 08 9388 0944
E: tony.dawe@ppr.com.au

ASX CODE
IGS

David Tasker, Director of IGS, stated: *“Part of our decision on the WG acquisition was driven by its unique ability to get to the forefront of the industry for a cost that is unparalleled. Additionally, the quality and experience of the team assembled by Julian Strauss should allow investors to enjoy a very high confidence interval in relation to a smooth glide-path to success.”*

Julian Strauss

Mr Strauss has been working as a licensed medical marijuana producer, researcher and agricultural hemp producer since 2007 in Sakatchewan, Canada with a focus on genetics, variety stabilisation through cell tissue culture, and proteomics and therapeutic expressions of cannabinoids in heirloom varieties.

This focus has taken Julian Strauss and Winter Garden to creating proprietary extractions and encapsulations for specific medical pathologies from pain management to revolutionary cancer and companion therapies to conventional oncological treatment. Through this process WG has done research in cellulose based polymers and biocomposites, energy production in the emergent industry of hemp as a solution to the cultural issues with THC.

Through his research Mr Strauss has created numeral proprietary formulations, technologies and agricultural systems that WG intends to bring to market to its unique position in the legalised hemp and cannabinoid research and development opportunity presented in Uruguay.

Daniel Sztern

Inter-regulatory Cooperation Liaison

Director of ENVIRO Consultants (Pimefil SA), a consultancy dedicated primarily to environmental studies including strategic environmental assessment (see experience www.enviro.com.uy).

Mr Sztern has held important positions in the Uruguayan Government, including the National Director of the Environment, Environmental Management of the state-owned water and sanitation company (OSE), as well as environmental consulting for several municipalities, advisor in the solid domestic waste plan for Congress Mayors, and advisor to the Minister of Economy on environmental and social issues.

As National Director of Environment Mr Sztern worked in the framework of strengthening environmental institutions, he worked directly with Parliament, organizing workshops and seminars for parliamentarians and local government authorities, environmental issues and decision making mechanisms in them, with special emphasis on education, climate change, erosion and environmentally sensitive areas.

Nils Rehmann Ph.D.

Pharmacology and Toxicology

Dr Rehmann is a chemist with strong expertise in chemical analytical techniques associated with extensive experience in leading laboratory teams and managing multiple projects simultaneously. He has worked with research bodies and industry in many different countries (New Zealand, Norway, Ireland, Canada, Germany and the US). Amongst his previous work he has created methodology for a governmental laboratory to facilitate QC testing for licensed producers under the MMPR legislation of Canada. In this capacity he has closely worked with Health Canada and stakeholders to create Standard Operating Procedures and validation protocols to analyse medical marijuana to meet regulatory guidelines.

Since October 2013 Dr Rehmann has been a Senior Consultant and Owner of NiRem Consulting Offering QC system build up and maintenance, lab optimisation, laboratory cost reduction, GMP compliance advice and lean labs implementation as well as business development and project management for R&D projects in the Life Science and Research & Technology sector. In this capacity along with his natural leadership abilities and outstanding networking skills, Dr Rehman has been helping Biotech companies to build and maintain their QA structure and satisfy regulatory compliance and marketability of products.

Dr Rehmann will be in charge of the standardisation and protocols for research in trials and development of industrial hemp. With his help Winter Garden Bioscience will create protocols for harvest, extraction, laboratory work and research specs, as well as lab build out, research overview, DNA, seed registration and breeding programs that far exceed any existing methodology and protocols in the world so far. His experience within the Canadian MMPR regulation will assist Uruguay to catapult itself to the new world standard in medical marijuana research, production for drug development and clinical trials.

Daniel Carbo, M.S.
Nanosystems Engineer

Mr Carbo is pursuing his Ph.D. in Biochemistry at the Chemical University of Uruguay (UDELAR) researching on signal transduction of CB1 and CB2 g- coupled protein human cannabinoid receptors. During his Masters thesis Mr. Carbo focused on Nano parameters of fibres in cellulose-based polymer systems and binders.

Mr Carbo will be in charge of the standardisation and protocols for research in trials and development of industrial hemp. Will create protocols for harvest, extraction, laboratory work and research specs, as well as lab build out, research overview, DNA, seed registration and breeding programs.

Oscar Florencio Caputi Vázquez
Agronomic Engineer

Mr Caputi is the Agronomic Engineer in charge of the research and legal aspects of the cannabis agriculture project, he is the representative behind WG's adaptation and breeding programs, and overseer of the registration and research of new cannabis genetics.

Mr Caputi has worked on several areas such as Development of Rural areas in Montevideo, Enviromental Aspects of Decentralisation. He has been in charge of several Committees for the Hiring of Agricultural engineers by the Uruguayan Government. He is currently the president of the committee to select agronomic engineer to develop governmental tasks.

Helena Pardo
Extraction Expertise

Mrs. Pardo is an expert in extraction technology with a Phd in Material chemistry from Uruguay's Universidad de la Republica. Her expertise in lipids encapsulation, micro/nano emulsion and medical delivery systems focused on surrogacy compound delivery and secondary metabolites modeled in the lab will be invaluable to our process. Helena's focus is as a project manager within our labs and the faculty of chemistry.

Sabina Vidal
Genetic Sequencing

Dr Vidal who did her doctorate in Molecular Genetics at Swedish University of agricultural sciences is the research leader for development projects focused on standardisation and genetic sequencing for seed development. Specifically Ms. Vidal will be focused on genetics research of heirloom cultivars, genetic stabilisation, CCE (controlled cultivation environments) and transgenic research within targeted phenotypes and species, genomics, bioinformatics, chemometric database, in silica modeling for drug development.

For and on behalf of the board



David Tasker
Director

FOR FURTHER INFORMATION, PLEASE CONTACT:

International Goldfields
T: +61 8 9488 5220

E: info@intgold.com.au

Professional Public Relations
Tony Dawe
T: +61 8 9388 0944
M: +61 405 989 743
E: tony.dawe@ppr.com.au